{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:57:52Z","timestamp":1760101072449},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00520-018-4367-y","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T02:34:03Z","timestamp":1533004443000},"page":"849-856","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database"],"prefix":"10.1007","volume":"27","author":[{"given":"Hirofumi","family":"Hamano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Zamami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keijo","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Imanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Chuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Izawa-Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Kirino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Teraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Yanagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"issue":"16","key":"4367_CR1","first-page":"4187","volume":"51","author":"Y Kawato","year":"1991","unstructured":"Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51(16):4187\u20134191","journal-title":"Cancer Res"},{"issue":"10","key":"4367_CR2","first-page":"1681","volume":"18","author":"S Takeuchi","year":"1991","unstructured":"Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T et al (1991) A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research groups of CPT-11 in gynecologic cancers. Gan To Kagaku Ryoho 18(10):1681\u20131689","journal-title":"Gan To Kagaku Ryoho"},{"issue":"2","key":"4367_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ygyno.2005.10.013","volume":"100","author":"K Matsumoto","year":"2006","unstructured":"Matsumoto K, Katsumata N, Yamanaka Y, Yonemori K, Kohno T, Shimizu C, Andoh M, Fujiwara Y (2006) The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 100(2):412\u2013416. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2005.10.013","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4367_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.1992.10.1.16","volume":"10","author":"M Fukuoka","year":"1992","unstructured":"Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N et al (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 10(1):16\u201320. \n                    https:\/\/doi.org\/10.1200\/jco.1992.10.1.16","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"16","key":"4367_CR5","first-page":"3752","volume":"56","author":"K Takasuna","year":"1996","unstructured":"Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56(16):3752\u20133757","journal-title":"Cancer Res"},{"issue":"5","key":"4367_CR6","first-page":"1136","volume":"7","author":"DF Kehrer","year":"2001","unstructured":"Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, Ruijgrok EJ, de Jonge MJ (2001) Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7(5):1136\u20131141","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4367_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1179>3.0.CO;2-3","volume":"92","author":"Y Takeda","year":"2001","unstructured":"Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, Kudo K (2001) Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 92(2):269\u2013275","journal-title":"Int J Cancer"},{"issue":"2","key":"4367_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/clpt.2008.152","volume":"85","author":"N Yamamoto","year":"2009","unstructured":"Yamamoto N, Takahashi T, Kunikane H, Masuda N, Eguchi K, Shibuya M, Takeda Y, Isobe H, Ogura T, Yokoyama A, Watanabe K (2009) Phase I\/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther 85(2):149\u2013154. \n                    https:\/\/doi.org\/10.1038\/clpt.2008.152","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"4367_CR9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1172\/JCI915","volume":"101","author":"L Iyer","year":"1998","unstructured":"Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101(4):847\u2013854. \n                    https:\/\/doi.org\/10.1172\/jci915","journal-title":"J Clin Invest"},{"issue":"7","key":"4367_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","volume":"17","author":"H Minami","year":"2007","unstructured":"Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N (2007) Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17(7):497\u2013504. \n                    https:\/\/doi.org\/10.1097\/FPC.0b013e328014341f","journal-title":"Pharmacogenet Genomics"},{"issue":"24","key":"4367_CR11","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60(24):6921\u20136926","journal-title":"Cancer Res"},{"issue":"206","key":"4367_CR12","doi-asserted-by":"publisher","first-page":"206ra140","DOI":"10.1126\/scitranslmed.3006548","volume":"5","author":"S Zhao","year":"2013","unstructured":"Zhao S, Nishimura T, Chen Y, Azeloglu EU, Gottesman O, Giannarelli C, Zafar MU, Benard L, Badimon JJ, Hajjar RJ, Goldfarb J, Iyengar R (2013) Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med 5(206):206ra140. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3006548","journal-title":"Sci Transl Med"},{"key":"4367_CR13","doi-asserted-by":"publisher","first-page":"26375","DOI":"10.1038\/srep26375","volume":"6","author":"T Nagashima","year":"2016","unstructured":"Nagashima T, Shirakawa H, Nakagawa T, Kaneko S (2016) Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism. Sci Rep 6:26375. \n                    https:\/\/doi.org\/10.1038\/srep26375","journal-title":"Sci Rep"},{"key":"4367_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5414\/CP202842","volume":"55","author":"M Fujimoto","year":"2017","unstructured":"Fujimoto M, Kanou M, Hosomi K, Takada M (2017) Angiotensin receptor blockers and the risk of cancer: data mining of a spontaneous reporting database and a claims database. Int J Clin Pharmacol Ther 55:295\u2013303. \n                    https:\/\/doi.org\/10.5414\/cp202842","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"4367_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/dmd.110.035451","volume":"39","author":"K Fujita","year":"2011","unstructured":"Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, Ishida H, Yamashita K, Mizuno K, Saji S, Ichikawa W, Yamamoto W, Nagashima F, Miya T, Narabayashi M, Ando Y, Hirose T, Sasaki Y (2011) Delayed elimination of SN-38 in cancer patients with severe renal failure. Drug Metab Dispos 39(2):161\u2013164. \n                    https:\/\/doi.org\/10.1124\/dmd.110.035451","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"4367_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s11095-013-1153-x","volume":"31","author":"K Fujita","year":"2014","unstructured":"Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y, Kato Y (2014) Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res 31(1):204\u2013215. \n                    https:\/\/doi.org\/10.1007\/s11095-013-1153-x","journal-title":"Pharm Res"},{"issue":"1","key":"4367_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Puijenbroek van","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310. \n                    https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"4367_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"issue":"28","key":"4367_CR19","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212. \n                    https:\/\/doi.org\/10.1200\/jco.2015.62.3488","journal-title":"J Clin Oncol"},{"issue":"2 Pt 1","key":"4367_CR20","first-page":"G232","volume":"254","author":"EL Renner","year":"1988","unstructured":"Renner EL, Lake JR, Cragoe EJ Jr, Van Dyke RW, Scharschmidt BF (1988) Ursodeoxycholic acid choleresis: relationship to biliary HCO-3 and effects of Na+-H+ exchange inhibitors. Am J Phys 254(2 Pt 1):G232\u2013G241","journal-title":"Am J Phys"},{"issue":"4","key":"4367_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<491::AID-IJC10>3.0.CO;2-M","volume":"83","author":"K Kobayashi","year":"1999","unstructured":"Kobayashi K, Bouscarel B, Matsuzaki Y, Ceryak S, Kudoh S, Fromm H (1999) pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 83(4):491\u2013496","journal-title":"Int J Cancer"},{"issue":"3","key":"4367_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1021\/js960085v","volume":"86","author":"WN Charman","year":"1997","unstructured":"Charman WN, Porter CJ, Mithani S, Dressman JB (1997) Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 86(3):269\u2013282. \n                    https:\/\/doi.org\/10.1021\/js960085v","journal-title":"J Pharm Sci"},{"issue":"9","key":"4367_CR23","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3109\/00498259109039556","volume":"21","author":"R Atsumi","year":"1991","unstructured":"Atsumi R, Suzuki W, Hakusui H (1991) Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21(9):1159\u20131169","journal-title":"Xenobiotica"},{"issue":"12","key":"4367_CR24","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/BF01535944","volume":"33","author":"T Khalil","year":"1988","unstructured":"Khalil T, Singh P, Fujimura M, Townsend CM Jr, Greeley GH Jr, Thompson JC (1988) Effect of aging on gastric acid secretion, serum gastrin, and antral gastrin content in rats. Dig Dis Sci 33(12):1544\u20131548","journal-title":"Dig Dis Sci"},{"issue":"6","key":"4367_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0531-5565(88)90058-7","volume":"23","author":"RS Maitra","year":"1988","unstructured":"Maitra RS, Edgerton EA, Majumdar AP (1988) Gastric secretion during aging in pyloric-ligated rats and effects of pentagastrin. Exp Gerontol 23(6):463\u2013472","journal-title":"Exp Gerontol"},{"issue":"5","key":"4367_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4196\/kjpp.2013.17.5.423","volume":"17","author":"JE Oh","year":"2013","unstructured":"Oh JE, Kim YW, Park SY, Kim JY (2013) Estrogen rather than progesterone cause constipation in both female and male mice. Korean J Physiol Pharmacol 17(5):423\u2013426. \n                    https:\/\/doi.org\/10.4196\/kjpp.2013.17.5.423","journal-title":"Korean J Physiol Pharmacol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4367-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4367-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4367-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T21:39:15Z","timestamp":1567028355000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4367-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["4367"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4367-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"4 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study and all protocols were reviewed and approved by the Ethics Committee of Tokushima University Hospital (approval number: 2059-4).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}